These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, and Sanofi Genzyme.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for metastatic castration-resistant prostate cancer. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Selection and Sequencing of Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

MODULE 2: Integration of PARP Inhibitors into the Management of mCRPC

MODULE 3: Novel and Investigational Strategies for mCRPC

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Learning Objectives

• Assess the available and emerging research database surrounding the optimal management of mCRPC, and apply recent advances to current clinical care.
• Establish an evidence-based approach to the selection, sequencing or combining of available therapeutic options for patients with mCRPC, considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biologic factors.
• Describe the rationale for testing patients with mCRPC for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about available data documenting the efficacy of PARP inhibition in specific settings.
• Evaluate the recent FDA approvals of olaparib and rucaparib for patients with mCRPC, and optimally incorporate these agents into clinical algorithms.
• Appreciate emerging Phase III data documenting the efficacy of 177Lu-PSMA-617 in patients with progressive PSMA-positive mCRPC, and consider the potential future clinical role of this strategy.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for patients with mCRPC, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Prof Chowdhury has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Armstrong — Advisory Committee: Advanced Accelerator Applications, Exelixis Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, FORMA Therapeutics, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Contracted Research (to Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, FORMA Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc. Prof Fizazi — Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, CureVac, Orion Corporation. Dr Morgans — Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exelixis Inc, Lantheus, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Sanofi Genzyme. Dr Sartor — Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Endocyte Inc, Invitae, Janssen Biotech Inc, Lantheus, Merck, Progenics Pharmaceuticals Inc, TeneoBio; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Myovant Sciences.

SURVEY PARTICIPANT — Alan H Bryce, MD — Advisory Committee: Merck; Contracted Research: Janssen Biotech Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, and Sanofi Genzyme.